CRIS Current Research Information System

RIZZELLO, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.632
NA - Nord America 1.423
EU - Europa 1.148
SA - Sud America 142
AF - Africa 129
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.479
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.386
VN - Vietnam 979
CN - Cina 597
SG - Singapore 562
IT - Italia 445
HK - Hong Kong 140
DE - Germania 125
GB - Regno Unito 121
KR - Corea 102
BR - Brasile 97
IN - India 81
SE - Svezia 77
FR - Francia 76
NL - Olanda 76
CI - Costa d'Avorio 52
FI - Finlandia 45
IE - Irlanda 39
JP - Giappone 34
RU - Federazione Russa 31
SC - Seychelles 29
PH - Filippine 25
AT - Austria 24
AR - Argentina 23
ZA - Sudafrica 23
BD - Bangladesh 22
BG - Bulgaria 16
CA - Canada 16
MX - Messico 16
ES - Italia 15
TG - Togo 13
TH - Thailandia 13
TW - Taiwan 11
JO - Giordania 10
CH - Svizzera 9
ID - Indonesia 9
PL - Polonia 9
IQ - Iraq 8
UA - Ucraina 8
EE - Estonia 7
TR - Turchia 7
UZ - Uzbekistan 6
BE - Belgio 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
SA - Arabia Saudita 5
CL - Cile 4
MY - Malesia 4
PK - Pakistan 4
AU - Australia 3
CO - Colombia 3
DZ - Algeria 3
NG - Nigeria 3
PE - Perù 3
PT - Portogallo 3
VE - Venezuela 3
CY - Cipro 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GH - Ghana 2
GR - Grecia 2
NO - Norvegia 2
NP - Nepal 2
PY - Paraguay 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
MN - Mongolia 1
MT - Malta 1
NZ - Nuova Zelanda 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
UY - Uruguay 1
ZM - Zambia 1
Totale 5.479
Salva come PNG Salva come JPEG
Città #
Singapore 397
Ho Chi Minh City 296
Hanoi 241
Hefei 213
Ashburn 208
Bologna 153
Hong Kong 135
Chandler 122
Dallas 122
Seoul 97
San Jose 93
Southend 73
Fairfield 63
Abidjan 52
Beijing 51
Haiphong 46
Dublin 39
Santa Clara 38
Lauterbourg 35
Los Angeles 33
New York 32
Woodbridge 31
Council Bluffs 29
Wilmington 28
Houston 26
Boardman 25
Milan 25
Seattle 25
Tokyo 25
Princeton 24
Cambridge 23
Helsinki 23
Munich 23
Hyderabad 22
Da Nang 20
Bengaluru 19
São Paulo 18
Frankfurt am Main 17
Lappeenranta 17
Ann Arbor 16
Biên Hòa 16
Sofia 16
Vienna 16
Amsterdam 15
Fabriano 14
Ha Long 14
Johannesburg 14
Quận Bình Thạnh 14
Turin 14
Bremen 13
Lomé 13
Redmond 13
Can Tho 12
Thái Nguyên 12
Buffalo 11
Guangzhou 11
Hải Dương 11
Amman 10
Chicago 10
Ninh Bình 10
Nuremberg 10
Redondo Beach 10
Atlanta 9
Dongguan 9
Nanjing 9
Quận Một 9
Điện Bàn 9
Bern 8
Bắc Ninh 8
Falkenstein 8
Jakarta 8
Nanchang 8
Tongling 8
Berlin 7
Bến Tre 7
Florence 7
London 7
Mexico City 7
Rome 7
Shanghai 7
Shenzhen 7
Zhengzhou 7
Dearborn 6
New Delhi 6
Orem 6
Padova 6
Paris 6
Quận Phú Nhuận 6
San Diego 6
Thu Dau Mot 6
Toronto 6
Vũng Tàu 6
Warsaw 6
Westminster 6
Ankara 5
Bắc Giang 5
Changsha 5
Huế 5
Long Xuyen 5
Redwood City 5
Totale 3.512
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 197
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 182
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 182
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 176
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 174
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 169
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 166
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 143
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 143
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 143
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 142
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 134
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 127
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 113
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 107
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 104
null 98
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 97
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 90
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 81
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 76
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 74
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 74
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 70
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 70
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 51
Totale 5.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.176
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.176
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 0 0 6 10 14
2021/2022301 7 13 15 37 14 12 12 25 16 46 56 48
2022/2023498 40 53 19 81 43 41 17 19 83 18 48 36
2023/2024262 17 29 15 19 18 53 9 54 6 17 17 8
2024/2025973 66 59 88 95 72 31 71 32 34 108 126 191
2025/20263.209 323 793 268 273 256 158 254 103 575 206 0 0
Totale 5.605